Related changes
Enter a page name to see changes on pages linked to or from that page. (To see members of a category, enter Category:Name of category). Changes to pages on your Watchlist are in bold.
16 September 2019
| m 17:24 | Hodgkin lymphoma (diff | hist) . . (+1) . . Jwarner (talk | contribs) (→Variant #3, uncapped vincristine {{#subobject:ff7478|Variant=1}}) |
| m 17:01 | Waldenström macroglobulinemia (diff | hist) . . (+1,177) . . Jwarner (talk | contribs) |
| m 16:19 | Mantle cell lymphoma (diff | hist) . . (+41) . . Jwarner (talk | contribs) (→BFR, then allo HSCT {{#subobject:c2659b|Regimen=1}}) |
| m 16:17 | Follicular lymphoma (2 changes | history) . . (+68) . . [Jwarner (2×)] | ||
| m | 16:17 (cur | prev) . . (+41) . . Jwarner (talk | contribs) (→Ibritumomab tiuxetan monotherapy {{#subobject:37ca7b|Regimen=1}}) | ||
| m | 16:03 (cur | prev) . . (+27) . . Jwarner (talk | contribs) |
15 September 2019
| m 17:12 | Diffuse large B-cell lymphoma (6 changes | history) . . (+1,013) . . [Jwarner (6×)] | ||
| m | 17:12 (cur | prev) . . (+5) . . Jwarner (talk | contribs) (→Regimen {{#subobject:60fc19|Variant=1}}) | ||
| m | 16:58 (cur | prev) . . (+13) . . Jwarner (talk | contribs) (→Chemotherapy) | ||
| m | 16:57 (cur | prev) . . (+977) . . Jwarner (talk | contribs) | ||
| m | 16:47 (cur | prev) . . (+10) . . Jwarner (talk | contribs) (→BR & Polatuzumab vedotin {{#subobject:1cc486|Regimen=1}}) | ||
| m | 16:47 (cur | prev) . . (+3) . . Jwarner (talk | contribs) (→BR & Polatuzumab vedotin {{#subobject:1cc486|Regimen=1}}) | ||
| m | 12:13 (cur | prev) . . (+5) . . Jwarner (talk | contribs) (→Regimen {{#subobject:e3e516|Variant=1}}) |
| 17:04 | Chronic lymphocytic leukemia (3 changes | history) . . (+1,562) . . [Jwarner (3×)] | ||
| 17:04 (cur | prev) . . (+1,545) . . Jwarner (talk | contribs) (→FCR {{#subobject:1dc12c|Regimen=1}}) | |||
| m | 08:56 (cur | prev) . . (+15) . . Jwarner (talk | contribs) (→Alemtuzumab monotherapy {{#subobject:ab5318|Regimen=1}}) | ||
| m | 08:55 (cur | prev) . . (+2) . . Jwarner (talk | contribs) (→Regimen {{#subobject:54cc87|Variant=1}}) |
| 16:52 | Follicular lymphoma (4 changes | history) . . (+3,029) . . [Jwarner (4×)] | ||
| 16:52 (cur | prev) . . (+1,660) . . Jwarner (talk | contribs) | |||
| m | 09:45 (cur | prev) . . (+3) . . Jwarner (talk | contribs) (→Variant #1 {{#subobject:f22c05|Variant=1}}) | ||
| m | 09:45 (cur | prev) . . (+1,358) . . Jwarner (talk | contribs) (→Ibritumomab tiuxetan monotherapy {{#subobject:b0c8fb|Regimen=1}}) | ||
| m | 09:39 (cur | prev) . . (+8) . . Jwarner (talk | contribs) (→Ibritumomab tiuxetan monotherapy {{#subobject:b0c8fb|Regimen=1}}) |
| m 16:40 | Hairy cell leukemia (2 changes | history) . . (+816) . . [Jwarner (2×)] | ||
| m | 16:40 (cur | prev) . . (+5) . . Jwarner (talk | contribs) (→Regimen {{#subobject:3d2dea|Variant=1}}) | ||
| m | 07:42 (cur | prev) . . (+811) . . Jwarner (talk | contribs) (→Cladribine monotherapy {{#subobject:dbcbf4|Regimen=1}}) |
| m 11:26 | Hodgkin lymphoma (diff | hist) . . (+5) . . Jwarner (talk | contribs) |
| m 11:25 | Small cell lung cancer (diff | hist) . . (+5) . . Jwarner (talk | contribs) |
| m 10:20 | Cutaneous T-cell lymphoma (diff | hist) . . (+21) . . Jwarner (talk | contribs) (→PUVA) |
14 September 2019
| m 22:44 | Cutaneous T-cell lymphoma (diff | hist) . . (+10) . . Jwarner (talk | contribs) (→Vorinostat monotherapy {{#subobject:6a3a5b|Regimen=1}}) |
| m 22:04 | Small cell lung cancer (diff | hist) . . (+3) . . Jwarner (talk | contribs) (→Variant #2, 1.5 mg/m2 {{#subobject:a08066|Variant=1}}) |
| m 13:34 | Hodgkin lymphoma (2 changes | history) . . (+983) . . [Jwarner (2×)] | ||
| m | 13:34 (cur | prev) . . (+431) . . Jwarner (talk | contribs) (→MOPP {{#subobject:bcde0|Regimen=1}}) | ||
| m | 13:32 (cur | prev) . . (+552) . . Jwarner (talk | contribs) (→MOPP {{#subobject:bcde0|Regimen=1}}) |
| m 11:02 | Hairy cell leukemia (diff | hist) . . (+589) . . Jwarner (talk | contribs) (→Interferon alfa-2b monotherapy {{#subobject:ca73f0|Regimen=1}}) |
13 September 2019
| m 23:48 | Marginal zone lymphoma (diff | hist) . . (+5) . . Jwarner (talk | contribs) (→Ibrutinib monotherapy {{#subobject:af879d|Regimen=1}}) |
| m 23:47 | Waldenström macroglobulinemia (2 changes | history) . . (+11) . . [Jwarner (2×)] | ||
| m | 23:47 (cur | prev) . . (+6) . . Jwarner (talk | contribs) | ||
| m | 23:47 (cur | prev) . . (+5) . . Jwarner (talk | contribs) (→Ibrutinib monotherapy {{#subobject:e206e9|Regimen=1}}) |
| m 23:45 | Chronic lymphocytic leukemia (3 changes | history) . . (-497) . . [Jwarner (3×)] | ||
| m | 23:45 (cur | prev) . . (-2) . . Jwarner (talk | contribs) | ||
| m | 14:34 (cur | prev) . . (+5) . . Jwarner (talk | contribs) (→Variant #2, 6 cycles {{#subobject:d30c3f|Variant=1}}) | ||
| m | 14:31 (cur | prev) . . (-500) . . Jwarner (talk | contribs) |
| m 23:42 | Mantle cell lymphoma (diff | hist) . . (+5) . . Jwarner (talk | contribs) (→Regimen {{#subobject:529650|Variant=1}}) |
| m 20:32 | Small cell lung cancer (2 changes | history) . . (+641) . . [Jwarner (2×)] | ||
| m | 20:32 (cur | prev) . . (+621) . . Jwarner (talk | contribs) (→Cisplatin & Etoposide {{#subobject:ec90cd|Regimen=1}}) | ||
| m | 13:52 (cur | prev) . . (+20) . . Jwarner (talk | contribs) |
| m 20:11 | Cutaneous T-cell lymphoma (2 changes | history) . . (+9) . . [Jwarner (2×)] | ||
| m | 20:11 (cur | prev) . . (+3) . . Jwarner (talk | contribs) (→Regimen {{#subobject:4e103c|Variant=1}}) | ||
| m | 20:10 (cur | prev) . . (+6) . . Jwarner (talk | contribs) (→Denileukin diftitox monotherapy {{#subobject:751a63|Regimen=1}}) |
| m 13:54 | Hodgkin lymphoma (diff | hist) . . (+10) . . Jwarner (talk | contribs) |
12 September 2019
| m 22:55 | Follicular lymphoma (2 changes | history) . . (+20) . . [Jwarner (2×)] | ||
| m | 22:55 (cur | prev) . . (+15) . . Jwarner (talk | contribs) | ||
| m | 11:28 (cur | prev) . . (+5) . . Jwarner (talk | contribs) |
| m 22:53 | Chronic lymphocytic leukemia (4 changes | history) . . (+35) . . [Jwarner (4×)] | ||
| m | 22:53 (cur | prev) . . (+3) . . Jwarner (talk | contribs) | ||
| m | 11:29 (cur | prev) . . (+5) . . Jwarner (talk | contribs) (→Regimen {{#subobject:5cabd0|Variant=1}}) | ||
| m | 11:27 (cur | prev) . . (+23) . . Jwarner (talk | contribs) | ||
| m | 11:02 (cur | prev) . . (+4) . . Jwarner (talk | contribs) (→Regimen {{#subobject:8e168d|Variant=1}}) |
11 September 2019
| m 18:07 | Peripheral T-cell lymphoma (diff | hist) . . (+5) . . Jwarner (talk | contribs) (→Regimen {{#subobject:fd7901|Variant=1}}) |
| m 18:07 | Cutaneous T-cell lymphoma (diff | hist) . . (+10) . . Jwarner (talk | contribs) (→Romidepsin monotherapy {{#subobject:b4c097|Regimen=1}}) |
| m 18:04 | Chronic lymphocytic leukemia (diff | hist) . . (+6) . . Jwarner (talk | contribs) |
| m 18:02 | Diffuse large B-cell lymphoma (diff | hist) . . (+3) . . Jwarner (talk | contribs) (→Variant #4, prednisone 100 mg, flat-dose vincristine {{#subobject:bcb2bf|Variant=1}}) |
